Rome-based VoiceMed reaches €1 million in total funding; launches pilot for early detection of chronic respiratory diseases

Rome-based digital health company VoiceMed has secured €1 million in total funding, marking a significant milestone for its voice-based solutions aimed at remote monitoring of chronic respiratory conditions. The funding round, which included public support from Invitalia and private investments from GCM Group, Padda Health, and 28Digital (formerly EIT Digital), will accelerate the company's efforts in clinical validation and real-world adoption. This investment underscores the recognized economic and social value of VoiceMed's innovative approach to healthcare. VoiceMed leverages artificial intelligence and vocal biomarkers to analyze breathing and voice recordings captured via standard smartphone microphones. Their fully digital, device-free platform applies machine-learning models to derive metrics linked to respiratory function, enabling earlier insights into patient health and supporting proactive, data-driven care models. This technology is designed for rapid deployment across primary care, hospital-at-home, and remote patient programs, aiming to enhance accessibility and efficiency in healthcare delivery. The company is launching a six-month pilot program in collaboration with Chiesi Group, a biopharmaceutical company focused on respiratory therapies, to further validate the early detection of chronic respiratory diseases like COPD. This initiative, utilizing VoiceMed's smartphone-based vocal biomarker platform, seeks to demonstrate how voice analysis can reduce hospital admissions and improve patient outcomes, especially as the global elderly population continues to grow. The pilot will also assess improvements in patient quality of life and potential reductions in emergency department visits.